Friday, January 22, 2021 2:28:00 AM
The investment was based on the Psychedelic ETF that launched yesterday. The same investors also did similar deals with the other companies included in the ETF. Also not sure how all you geniuses expect Revive to fund all their Trials and Research when they are literally generating $0.00 revenue. With this 40M sale the OS goes to 300M which for a Pharmaceutical company is low. They also just added two more Trial sites which indicates that the Trial is expanding. Not sure why a company would be expanding it's Trials if it wasn't showing good results!?!
2020!!!!!
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
